You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Li C, Fort M, Liang L, et al
718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0718